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Abstract
Background: Liver metastasis is the most common cause of death in patients with colorectal cancer. Despite extensive
research into the biology of cancer progression, the molecular mechanisms that drive colorectal cancer metastasis are not
well characterized.
Methods: HT29 LM1, HT29 LM2, HT29 LM3 cell lines were derived from the human colorectal cancer cell line HT29 following
multiple rounds of in vivo selection in immunodeficient mice.
Results: CD44 expression, a transmembrane glycoprotein involved in cell-cell and cell-matrix adhesions, and cancer cells
adhesion to endothelial cells was increased in all in vivo selected cell lines, with maximum CD44 expression and cancer cells
adhesion to endothelial cells in the highly metastatic HT29 LM3 cell line. Activation of c-Met upon hepatocyte growth factor
(HGF) stimulation in the in vivo selected cell lines is CD44 independent. In vitro separation of CD44 high and low expression
cells from HT29 LM3 cell line with FACS sorting confirmed that c-Met activation is CD44 independent upon hepatocyte
growth factor stimulation. Furthermore, in vivo evaluation of CD44 low and high expressing HT29 LM3 cells demonstrated
no difference in liver metastasis penetrance.
Conclusions: Taken together, our findings indicate that the aggressive metastatic phenotype of in vivo selected cell lines is
associated with overexpression of CD44 and activation of c-MET. We demonstrate that c-Met activation is CD44
independent upon hepatocyte growth factor stimulation and confirm that CD44 expression in HT29 LM3 cell line is not
responsible for the increase in metastatic penetrance in HT29 LM3 cell line.
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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-
related deaths in the United States [1]. Metastatic or recurrent
disease is the most common cause of death in these patients. The
prognosis for CRC is based on the formation of distant metastases,
not the primary tumor itself. Even with comprehensive research
into the biology of cancer progression, the molecular mechanisms
involved in the metastatic cascade are not well characterized.
The mechanisms of metastasis involve a selective and sequential
series of steps, including separation from the primary tumor,
invasion through surrounding tissues, entry into the circulatory
system, and the establishment and proliferation in a distant
location [2]. Two proteins that have been shown to be involved
with multiple steps of the metastatic cascade are CD44 and c-
MET. CD44, a transmembrane glycoprotein that belongs to a
family of cell adhesion molecules, is involved with the progression
and metastasis of multiple types of cancer [3–6] and has been
associated with a poor prognosis in CRC patients [3]. c-MET is a
proto-oncogene that encodes for the receptor tyrosine kinase, also
known as hepatocyte growth factor receptor [4]. The only known
ligand for c-MET is hepatocyte growth factor (HGF); both c-MET
and HGF are upregulated in a number of malignancies and are
associated with a poor prognosis and an early predictor of further
metastasis [5]. Specifically, c-MET is involved in the regulation of
proliferation, motility, invasion and metastasis via its phosphory-
lation and activation of downstream signaling pathways [4].
A comprehensive understanding of the mechanisms that drive
CRC metastasis is important for the development of novel
approaches to treat this cancer. Therefore, the purpose of our
study was to identify the genes that promote liver metastasis in
CRC. Here, we established three highly metastatic CRC cell lines
and show that their more aggressive metastatic phenotype is
associated with an increase in CD44 expression and activation of
c-MET. Furthermore, we show that the activation of c-MET was
independent of the levels of CD44 present. Finally, we demon-
strate that increased CD44 expression is not responsible for the
increase in metastatic penetrance the of HT29 LM3 cell line.
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Importantly, in vivo selection and isolation of liver-tropic CRC
metastatic cells allowed us to study the biological mechanisms of
CRC cancer metastasis and identify the mechanisms contributing
to liver metastasis in CRC.
Materials and Methods
Cell Lines, Transfections
HT29 cells and Human Lung Microvascular Endothelial Cells
(HMVEC-L) were obtained from American Type Culture
Collection (Manassas, VA), were previously authenticated in
November 2011 by Genetica DNA Laboratories (Cincinnati,
OH) were cultured in McCoy’s 5A medium, purchased from
Sigma Aldrich (St. Louis, MO) supplemented with 10% FBS and
antibiotic-antimycotic. EGFP-N1 vector was purchased from
Clontech (Mountain View, CA). GFP-expressing cells were
selected with 500 mg/ml Geneticin (G418), purchased from Life
Technologies (Carlsbad, CA) and enriched by three cycles of
fluorescence-activated cell sorting (FACS). Pre-made pGL3 firefly
luciferase (luc) lentiviral particles were purchased from Lentigen
(Gaithersburg, MD). For lentiviral transduction, 5000 cells/well
were seeded in 96 well tissue culture plates and infected the
following day with luc lentiviral particles at a MOI of 10 in the
presence of 10 mg/ml polybrene, purchased from Santa-Cruz
Biotechnology (Dallas, TX).
Liver Metastasis Model and in vivo Imaging
Male athymic NCr nude mice between 6–8 wks of age were
purchased from Taconic (Hudson, NY). Housing for these animals
was maintained in a HEPA-filtrated environment within sterilized
cages with 12 h light/12 h dark cycles. All animal procedures were
conducted with approval of and in compliance with University of
Kentucky Institutional Animal Care and Use Committee; protocol
#2009-0529. For intrasplenic injection of CRC cells athymic NCr
nude mice were anesthetized with isoflurane (induction 4%,
maintenance 2%). A 1 cm cutaneous incision was made in the left
flank and carried down through the peritoneal wall. The spleen
was carefully exposed, and HT29 GFP-Luc cells (56106 cells/
100 ml) were injected under the spleen capsule using a 27-gauge
needle. The viability of cells used for inoculation was greater than
95% as determined by Vi-CELL XR (Beckman Coulter). Gentle
pressure was applied to the inoculation site until there was no
visible sign of bleeding. LIGACLIP extra single clip ligating
applier with titanium LIGACLIP extra ligating clips, purchased
from Ethicon (San Angelo, TX), was used to clip lienal and lieno-
pancreatic veins 5 min after splenic injection of CRC cells; the
spleen was then removed. The mice were sacrificed after 4 wks or
sooner if moribund. Liver tissues were preserved for histological
examination by fixation in 10% buffered formalin followed by
paraffin embedding.
All bioluminescent images were acquired with an IVIS
Spectrum (Caliper Life Sciences, Hopkinton, MA), with the stage
heated to 37uC during live cell imaging. Images were acquired
10 min after i.p. injection of D-Luciferin (150 mg/kg) using 15 sec
exposure. GFP fluorescence imaging was performed using an LT-
9500 Illumatool/TLS (Lightools Research, Encinitas, CA),
equipped with an excitation source (470 nm) and filter plate
(515 nm).
Enzymatic Isolation of CRC Cells from Liver Metastases
Liberase DH Research Grade (05401054001; Roche Applied
Science) was resuspended in sterile water to 2.5 mg/ml concen-
tration and stored in single-use 100 ml aliquots at280uC.
Collagenase/Hyaluronidase (07912; StemCell Technologies) was
aliquoted into single-use 250 ml aliquots and stored at 280uC.
Upon collection, metastatic tumors were placed into complete cell
culture media supplemented with 1X Gibco Antibiotic-Antimy-
cotic (15240-062; Life Technologies) for transportation. Metastatic
tumor fragments were minced into 2-mm cubes using scissors and
digested in 50 mg/ml Liberase DH (100 ml) and 0.5X Collage-
nase/Hyaluronidase (250 ml), diluted in 5 mL of McCoy5A serum
free media for 4 h at 37uC with gentle agitation by magnetic
stirring bar. No undigested tissue was observed. Digested cells
were washed twice with complete cell culture media and
transferred into 10% FBS McCoy5A media supplemented with
1X Gibco Antibiotic-Antimycotic and 100 mg/ml Primocin (ant-
pm-1; InvivoGen).
Western Blot Analysis and Antibodies
Total protein lysates (20 mg) were resolved on a 4–12% bis-tris
gel and transferred to Immobilon PVDF transfer membranes.
Membranes were incubated for 40 min at room temperature in
blocking solution (TRIS-buffered saline containing 5% nonfat
dried milk and 0.1% Tween 20), followed by an overnight
incubation in primary antibodies at 4uC. Membranes were then
washed 3 times and incubated with horseradish peroxidase–
conjugated secondary antibodies for 1 h. After 3 additional
washes, the immune complexes on the membranes were visualized
by ECL detection.
The following antibodies were purchased and utilized in our
study: Cell Signaling (Danvers, MA): phospho-AKT (#4058), total
AKT (#2920), AKT2 (#3063), phospho-ERK 1/2 (#4695), total
ERKK (#9107), PTEN (#9559), phospho-mTOR (#2971), total
mTOR (#2972), phospho-MET (#3129 for western blotting and
#3077 for IHC), c-MET (#3148), CD44 (#3570), phospho-beta
catenin (#4176), phospho-FAK (#8556), and total FAK (#3285).
Santa Cruz (Dallas, TX): AKT 1 (#5298). BD (San Jose,
California): Beta catenin (#610154) and E-cadherin (#610404).
Abcam (Cambridge, MA): KRAS (#55391). Millipore (Billerica,
MA): p85a (#05-212). All antibodies were used at a concentration
of 1:1,000.
siRNA Transfections and HGF Cell Treatment
For HGF, treatment cells were seeded at a concentration of
800,000 cells/well in a six well plate. After 24 h, the cell media
was changed to serum free media for an additional 24 h.
Recombinant human HGF (PeproTech #100-39) was then added
to the wells at a concentration of 50 ng/mL for 5 min. siRNA
transfections: ON-TARGET plus CD44 siRNAs (LU-00999907,
LU-00999908) and control siRNA (D-001810-10) were purchased
from Dharmacon (Lafayette, CO) and used in a concentration of
100 mM.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previously
described [6]. The paraffin-sections were deparaffinized in xylene
and rehydrated in descending ethanol series. Protein staining was
performed using DAKO EnVision Kit, purchased from Dako
Corp. (Carpinteria, CA). CD44 and p-MET antibodies were used
at a concentration of 1:100 in DAKO antibody diluent. All
sections were counterstained with hematoxylin and observed by
light microscopy.
Proliferation Assay
Parental HT29 and HT29 LM3 cells were plated in 24-well
plates at a density of 25,000 cells per well. Proliferation was
CD44 and c-Met Expression in CRC Metastasis
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assessed by cell counting at 24, 48, and 72 h, using a Beckman-
Coulter Vi Cell XR cell viability analyzer (Fullerton, CA).
Endothelial Cell Adhesion Assay
Human microvascular endothelial cells from lungs (HMVEC-L)
were activated with 15 ng/mL of TNFa for 4 h. Parental HT29
and HT29 LM3 cells were labeled with Calcein AM (2.5 mg/mL
final concentration) for 30 min at 37uC, washed, and added atop
the monolayer of activated HMVEC-L cells for 30 min. Unat-
tached cells were removed by washing with PBS (5x) and three
GFP images were taken per well to count the attached cells.
Flow Cytometry Analysis and Cell Sorting
HT29 LM3 cells were labeled with CD442 Alexa Fluor 647
antibody (Biolegend) at a concentration of 2.5 mg/mL per 107 cells
for 30 min. The cells were washed and resuspended in sorting
buffer (1X phosphate buffered saline, 1 mM EDTA, 25 mM
HEPES, 1% heat-inactivated fetal bovine serum). Within a sample
of HT29 LM3 cells, we sorted two populations of cells: 10% of the
cells with a high expression of CD44 (abbreviated as HT29 LM3
CD44+) and cells that do not express CD44 (abbreviated as HT29
LM3 CD442). Unstained HT29 LM3 cells were used as a
negative control. Following cell sorting, the cells were expanded in
cell culture. The UK Flow Cytometry Service Facility conducted
cell analysis and cell sorting.
Results
In vivo Selection Process of Liver-tropic CRC Metastatic
Cells
CRC liver metastasis is a multistage process in which malignant
cells spread from a primary tumor to colonize the liver. Malignant
cells are invasive and metastatic; however, only a restricted
fraction of the cells in a primary tumor are considered to be highly
metastatic. In vivo selection methods, using primary cancer cell
lines and comparison between pure clonal populations of isolated
liver-tropic metastatic cells is a useful scientific approach for the
identification of biological mechanisms enhanced during CRC
liver metastasis.
In this study, we engineered the HT29 CRC cell line to express
reporter plasmids, GFP and firefly luciferase that permits
fluorescence and bioluminescence imaging in a single experimen-
tal model, and performed in vivo selection of HT29 cells that
metastasized to the liver. Briefly, HT29 cells were injected into the
spleen of athymic nude mice; splenectomy was performed 5 min
after intrasplenic injection of CRC cells to avoid re-metastasis.
Experimental liver metastases (LM; 30–40 metastatic lesions) were
harvested, established in tissue culture, and designated as the
HT29 LM cell lines. Cells harvested from these cultures were
injected into the spleen of another set of nude mice. The sequence
of in vivo selection is shown in Figure 1A. HT29LM1 and HT29
LM3 vary dramatically with respect to their metastatic potential.
Bioluminescent imaging of mice injected with HT29 LM2
demonstrated a 2.5-fold increase in penetrance compared to
parental cell line (,3.5 wks with ,100% penetrance vs. ,4 wks
with ,40% penetrance) (Figure 1B). Thus, in vivo selection of
HT29 cell lines provided highly metastatic cells for comparison to
parental cells under isogenic background.
The c-MET Pathway is Upregulated in the HT29 Derived
Cell Lines
Molecular analysis of cancer cells in various stages of
progression have revealed that alterations in tumor suppressor
genes and oncogenes accumulate during tumor progression and
correlate with the clinical aggressiveness of cancer. Next, we
performed comparative analysis of several oncogenes and tumor
suppressor gene expression profiles in HT29 LM cell lines by
Western blot. Figure 2 demonstrates that the phosphorylation of
c-MET was dramatically increased in the HT29 LM1 and HT29
LM2 cell lines, with the highest activation in the HT29 LM3 cell
line, as compared to the parental HT29 cells. We observed a slight
increase in total c-MET protein as well. These changes were noted
when cells were cultured in normal or serum-free conditions
(separate experiments). Western blot analysis of protein extracts
from HT29 LM cell lines did not show any changes in pAkt
(Ser473), Akt, p85a, PTEN, pERK(Tyr 1234/1235), ERK, k-Ras
protein expression (data not shown). Together, these findings
suggest that an increase in the metastatic potential of HT29
derived cell lines is associated with activation of the c-MET
pathway.
Expression of CD44 Protein is Significantly Increased in
the HT29 Derived Cell Lines
The expression of key proteins in the CD44, b-catenin, and
FAK pathways, which play an important role in CRC metastasis
[7–9] was analyzed next. We observed a gradual increase of high
molecular weight CD44 expression observed at ,150 kDa in
HT29 LM cell lines, with maximum CD44 expression in HT29
LM3 compared to the parental HT29 cell line (Figure 3A).
Western blot analysis of protein extracts from HT29 LM cell lines
did not show any changes in p-b-Catenin (S675), b-Catenin, p-
FAK(Tyr397) and FAK protein expression (data not shown). To
further confirm our in vitro findings, we analyzed parental HT29
and HT29 LM3 liver metastasis tissue sections by IHC. Consistent
with Western blot analysis, expression of both p-MET and CD44
was significantly increased in HT29 LM3 as compared to HT29
LM1 (Figure 3B). CD44 cell surface flow cytometry analysis also
demonstrated higher level of CD44 expression on the surface of
HT29 LM3 cells compared to parental HT29 cells (Figure 3C).
Together, these data suggest that enhanced metastatic potential of
the HT29 LM cell lines is associated with an increase in CD44
expression.
High Level of c-MET Activation in HT29 LM3 is
Independent of CD44 Expression
Met is an essential receptor tyrosine kinase (RTK) that induces
cancer cells proliferation, differentiation, migration and survival
[10]. Met is transiently activated after HGF induction and requires
specific CD44 isoforms for its activation in various cancers [11,12].
To better understand the interaction between MET activation and
CD44 in the parental HT29 and HT29 LM3 cells, we analyzed
the effects of HGF stimulation in both cell lines. As shown in
Figure 4A, HGF-treatment increases activation of c-MET in both
parental HT29 and HT29 LM3, with slightly higher activation in
the HT29 LM3 cell line as compared to the parental HT29 cell
line. We next transfected HT29 LM3 cells with siRNA against all
CD44 isoforms and then treated these cells with HGF. Figure 4B
demonstrates similar levels of c-MET phosphorylation in the
presence or absence of HGF, suggesting that activation of the c-
MET pathway in HT29 LM3 cells is independent of CD44
expression.
IHC analysis of CD44 in HT29 LM3 tissue sections demon-
strated variable CD44 expression in liver metastases; clusters of
liver metastases with high expression of CD44 next to metastases
with low CD44 expression (Figure 4C). To further analyze this
phenomenon, we used flow cytometry and cell sorting to isolate
CD44 and c-Met Expression in CRC Metastasis
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two populations of cells based on cell surface CD44 expression.
Two cell lines with high CD44 expression (HT29 LM3 CD44+)
and low CD44 expression (HT29 LM3 CD442) were established
(Figure 4D). CD44 expression in these cell lines was confirmed by
Western blot analysis. Both CD44+ and CD442 cell lines had
higher activation of c-Met compared to the parental cell line
(Figure 4E).
To further confirm that activation of c-MET is independent of
CD44 expression in the HT29 LM3 cell line, CD44+ and CD442
cell populations were stimulated with HGF and analyzed by
Western blot. As shown in Figure 4F, a similar level of c-MET
activation in CD44+ and CD442 cells was observed. Therefore,
we show that the level of CD44 expression in in vivo trained HT29
LM3 cells does not correlate with c-Met activation levels by its
natural ligand, HGF, further confirming that c-MET acts
independently of CD44 in the HT29 LM3 cell line.
Aggressive Metastatic Behavior of HT29 LM3 is
Associated with an Increased Ability to Adhere to
Endothelial Cells but is not Driven by CD44 Expression
Cancer cell adhesion to endothelial cells is an important step of
metastasis and is known to be regulated by CD44 in many cancer
cells [13]. HT29 LM3 and parent HT29 cell lines were labeled
with Calcein AM and HT29 LM3 binding ability to endothelial
cells was evaluated with in vitro adhesion assay. We demonstrated
that HT29 LM3 cells had an increased ability to attach to
endothelial cells, as compared to parental HT29 cells (Figure 5A).
These results suggest that the more aggressive metastatic
phenotype of HT29 LM3 cells is may be the result of increased
cellular adhesion to endothelial cells.
Figure 1. Establishment of HT29 derived cell lines with enhanced metastatic potential. (A) Illustration of metastatic CRC in vivo selection
process. Experimental liver metastases were harvested, established in culture and designated HT29 LM1, LM2, and LM3 cell lines. (B) Bioluminescent
images of mice 4 wks after intrasplenic injection of parental HT29 and HT29 LM2 cell lines.
doi:10.1371/journal.pone.0097432.g001
Figure 2. The aggressive metastatic phenotype of the HT29
LM1, LM2, and LM3 cell lines is associated with the activation
of the c-MET pathway. HT29 LM1, LM2, LM3 and parental cell line
were cultured in normal medium for 24 h (first 4 lanes). In another
experiment, cells were cultured in serum free medium for 24 h and
stimulated with complete medium for 10 min (remaining 4 lanes).
Protein expression profiles were analyzed by Western blot. b-actin was
used as a loading control.
doi:10.1371/journal.pone.0097432.g002
CD44 and c-Met Expression in CRC Metastasis
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Our in vitro analysis of in vivo selected HT29 cell lines identified
an increase in CD44 expression and c-Met activation. Since
adhesion to endothelial cells is a first crucial rate-limiting step of
hematogenous CRC liver metastasis after intrasplenic injection
and the CD44 receptor is known to regulate cancer cells
adhesion [7,12], we next evaluated role of CD44 on CRC
metastasis in vivo. HT29 LM3 CD44+ and HT29 LM3 CD442
cells were injected into the spleens of athymic nude mice. Four
wks post injection, fluorescent GFP imaging of CRC liver
metastases was performed. As shown in Figure 5B, the level of
CD44 expression did not have any significant effect on CRC
liver metastasis. CD44 expression level in CD44+ and CD442
liver metastases was confirmed with IHC staining. Collectively,
these findings suggest that overexpression of CD44 alone is not
sufficient to enhance CRC liver metastasis and that other
pathways are likely involved.
Discussion
The most devastating aspect of CRC is the emergence of liver
metastases, which is responsible for the majority of deaths from
this disease. Thus, to understand the molecular mechanisms of
metastasis is one of the most important issues in cancer research.
According to the concept of tumor cell heterogeneity, highly
metastatic cells are present as a sub-population in a primary
tumor [14]. At present, it is impossible identify metastatic and
non-metastatic cells in the primary tumor. In this study, we
utilized an in vivo selection model to identify molecular markers
for the prediction of metastatic potential of CRC cells. This
model of injecting cancer cells into the spleen, harvesting hepatic
metastases, and re-injecting into the spleen, creates highly
metastatic cell lines as confirmed by a greater number of lymph
and liver metastases [15]. Similarly, our study demonstrated that
the cells created through in vivo selection cycle yielded extensive
liver metastasis and that aggressive behavior of these cells is
associated with alterations in CD44 expression, c-MET activity
and increased ability of CRC cells to adhere to endothelial cells.
Therefore, the model of in vivo selection for metastatic cells can be
a useful tool for studying genetic changes occurring in cells when
they acquire the metastatic phenotype. Furthermore, the
utilization of this model allows for a better understanding of
the mechanisms that drive cancer progression and can be used as
a tool to discover and develop potential therapeutic targets for
CRC metastasis.
c-MET and CD44 are co-expressed in a number of cancers,
such as pancreatic cancer and CRC [16,17]. Pancreatic cancer
cells with a high expression of both c-MET and CD44 were shown
to have a greater tumorigenic potential [17]. Furthermore,
expression of both proteins have been correlated with a shorter
patient survival period in CRC [3], and a recent study from our
laboratory showed that CD44 and c-MET activation is associated
with an increase in CRC metastasis [18]. Consistent with these
findings, the results of our current study demonstrate that an
increase in both the expression of CD44 and the activation of c-
MET correlates with an increase in the metastatic potential of the
HT29 LM3 cell line. CD44 and c-MET collaboration, and their
interactions on the plasma membrane, lead to the activation of
downstream signaling pathways that promote cancer progression
[19–21]. On the other hand, several studies have found that the
activation of c-MET is independent of CD44 [22,23]. Our results
suggest that in the HT29 LM3 cell line, CD44 and c-MET act
independently in the presence or absence of HGF, a c-MET
ligand. Discrepancies between studies could be explained by
differences in the cell lines used and indicate that the extent of the
interaction between CD44 and c-MET may be cell type specific.
As both proteins have been associated with a poor prognosis in a
multitude of cancers, the further study of their interaction in
metastatic cell lines is critically important and may lead to new
therapeutic targets.
To better understand the role of CD44, we utilized two
populations of HT29 derived cells, CD44+ and CD442.
Interestingly, our data suggests that CD44 is not the key protein
driving the HT29 derived cells to become increasingly metastatic
and that most likely, c-Met activation or other pathways enhance
CRC liver metastasis. In our model, CD44 and c-MET signal
independently, which indicates that c-MET signaling is not
impaired in CD442 cells and continues to drive metastasis.
Additionally, there are many isoforms of CD44, due to alternative
Figure 3. Expression of CD44 is significantly increased in the
HT29 LM1, LM2, and LM3 cell lines. (A) HT29 LM1, LM2, LM3 and
parental cell line were cultured in normal medium for 24 h. Protein
expression profiles were analyzed by Western blot. b-actin was used as
a loading control. (B) IHC analysis of CD44 and p-MET expression in
HT29 LM1 and HT29 LM3 liver metastasis tissue sections. (C) Flow
cytometry analysis of CD44 geometric mean fluorescence intensity in
parental HT29 and HT29 LM3 cells.
doi:10.1371/journal.pone.0097432.g003
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splicing, that play different roles in metastasis, which may explain
the discrepancy between the roles of CD44 in metastasis. Each
isoform plays a different role in cancer cells and some cancers only
express one of the isoforms while others express multiple isoforms
[7]. Therefore determining the exact function that CD44 plays in
each cancer cell line becomes increasingly important for the
utilization of CD44 as a therapeutic target.
Conclusions
A thorough understanding of the genetic mechanisms that
initiate the metastatic cascade and promote CRC metastasis
progression in the liver is important for the development of novel
anticancer therapies. Pure clonal populations of isolated liver-
tropic metastatic cells allowed us to selectively study and compare
Figure 4. CD44 independent c-MET activation in HT29 LM3 cells. (A) Analysis of CD44, p-MET, c-MET, p-AKT and AKT expression in parental
HT29 and HT29 LM3 after HGF stimulation (50 ng/mL; 5 min) by Western blot. b-actin was used as a loading control. (B) HT29 LM3 cells were
transfected with CD44 siRNA and stimulated with HGF (50 ng/mL; 5 min) 24 h after siRNA transfection. (C) CD44 expression in HT29 LM3 and
parental HT29 liver metastasis tissue sections were analyzed by IHC. (D) HT29 LM3 cells were sorted for high and low CD44 expression. Cells were
gated and sorted to collect 10% of the cells with high CD44 expression and cells with low CD44 expression. (E) Analysis of CD44, p-MET, and c-MET
expression in parental HT29, HT29 LM3 CD442, and HT29 LM3 CD44+ cells. (F) Analysis of p-MET, c-MET, CD44, p-AKT, and AKT expression in parental
HT29, HT29 LM3 CD442, and HT29 LM3 CD44+ cells after HGF (50 ng/mL; 5 min) stimulation.
doi:10.1371/journal.pone.0097432.g004
CD44 and c-Met Expression in CRC Metastasis
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biological mechanisms mediating CRC metastasis to liver. Taken
together, our findings indicate that the aggressive metastatic
phenotype of the in vivo selected HT29 cell line is associated with
overexpression of CD44 and activation of c-MET. We demon-
strate that c-Met activation is CD44 independent upon HGF
stimulation and confirm that CD44 expression in HT29 LM3 cell
line is not responsible for the increase in metastatic penetrance in
HT29 LM3 cell line. Importantly, we demonstrate that the model
of in vivo selection for CRC metastatic cells represents a valuable
tool to identify the mechanisms contributing to liver metastasis in
CRC and identify molecular pathways for a targeted therapy of
CRC liver metastasis.
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